TargetMol

XR-5000

Product Code:
 
TAR-T29168
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T29168-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T29168-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T29168-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
XR-5000 is a DNA topoisomerase I and II inhibitor.
CAS:
89459-25-6
Formula:
C18H19N3O
Molecular Weight:
293.37
Purity:
0.98
SMILES:
CN(C)CCNC(=O)c1cccc2cc3ccccc3nc12

References

1. Soo JC, Lee EG, Lee LA, Kashon ML, Harper M. Evaluation of pump pulsation in respirable size-selective sampling: Part III. Investigation of European standard methods. Ann Occup Hyg. 2014 Oct;58(8):1006-17. doi: 10.1093/annhyg/meu047. PubMed PMID: 25053700; PubMed Central PMCID: PMC4702258. 2. Saleem A, Aboagye EO, Matthews JC, Price PM. Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes. Cancer Chemother Pharmacol. 2008 Apr;61(5):865-73. PubMed PMID: 17639391. 3. Gilroy KL, Leontiou C, Padget K, Lakey JH, Austin CA. mAMSA resistant human topoisomerase IIbeta mutation G465D has reduced ATP hydrolysis activity. Nucleic Acids Res. 2006 Mar 20;34(5):1597-607. PubMed PMID: 16549872; PubMed Central PMCID: PMC1405819. 4. Dittrich C, Dieras V, Kerbrat P, Punt C, Sorio R, Caponigro F, Paoletti X, de Balincourt C, Lacombe D, Fumoleau P. Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer. Invest New Drugs. 2003 Aug;21(3):347-52. PubMed PMID: 14578683.